bendamustine + erlotinib

Bendamustine + erlotinib is an investigational combination therapy consisting of two small molecule drugs: bendamustine, a bifunctional alkylating agent, and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Bendamustine induces cell death primarily through DNA cross-linking and damage, leading to apoptosis in both proliferating and quiescent cells. Erlotinib inhibits the intracellular phosphorylation of EGFR tyrosine kinase, blocking downstream signaling pathways that promote cancer cell proliferation and survival. This combination was studied in a phase I clinical trial for metastatic triple-negative breast cancer (TNBC), based on the rationale that TNBC often overexpresses EGFR and is sensitive to DNA-damaging agents. However, the regimen resulted in excessive toxicity—particularly severe and prolonged lymphopenia with increased risk of opportunistic infections—and was not recommended for further development[1][4].